Impact of SARS-CoV-2 mRNA-BNT162b2 vaccination on survival outcomes in metastatic colorectal cancer patients treated with bevacizumab-based therapy.
Abstract
3574 Background: Colorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide. Bevacizumab, an anti-vascular endothelial growth factor (VEGF) antibody, is widely used in metastatic CRC (mCRC) treatment to inhibit tumor angiogenesis and modulate the immunosuppressive tumor microenvironment. Recent evidence suggests that mRNA-based COVID-19 vaccines, such as SARS-CoV-2 mRNA-BNT162b2, may enhance anti-tumor immune responses. This study aimed to evaluate the impact of SARS-CoV-2 mRNA-BNT162b2 vaccination on progression-free survival (PFS) and overall survival (OS) in mCRC patients treated with bevacizumab-based therapy. Methods: This retrospective, single-center study included 92 mCRC patients treated with bevacizumab between June 2021 and October 2024. Patients were divided into vaccinated (n=50) and unvaccinated (n=42) groups. Baseline demographic, clinical, and pathological characteristics were collected. PFS and OS were analyzed using Kaplan-Meier estimates and Cox proportional hazards regression models to identify independent predictors of survival. Results: The vaccinated group demonstrated significantly longer median PFS (8.0 months vs. 5.6 months, p=0.010) and OS (39.4 months vs. 17.8 months, p=0.014) compared to the unvaccinated group. Multivariate analysis identified SARS-CoV-2 mRNA-BNT162b2 vaccination as an independent predictor of improved PFS (HR 0.44, p=0.003) and OS (HR 0.39, p=0.018). Vaccinated patients also had a higher proportion of favorable ECOG PS and a lower prevalence of RAS mutations. Conclusions: SARS-CoV-2 mRNA-BNT162b2 vaccination was associated with improved PFS and OS in mCRC patients receiving bevacizumab-based therapy, potentially through enhanced anti-tumor immune responses. These findings highlight the potential of mRNA-based vaccines to modulate the tumor microenvironment and improve outcomes in mCRC. Further prospective studies are needed to confirm these results and explore underlying mechanisms.
Article Details
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
Authors (6)
Coskun Yazgan
Ankara University School of Medicine, Department of Medical Oncology, Ankara, Turkey; Ankara University Cancer Institute, Ankara, Turkey, Ankara, Turkey
Beliz Bahar Karaoğlan
Erman Akkus
Erman Akkus, MD, Department of Medical Oncology, Faculty of Medicine, Ankara University, Ankara, Turkey
Mehmet Berk Oruncu
Ankara University School of Medicine, Department of Medical Oncology, Ankara, Turkey; Ankara, Ankara, Turkey
Hakan Akbulut
Gungor Utkan
Ankara University Faculty of Medicine, Medical Oncology Department, Ankara, Turkey